Vor Biopharma (VOR) Profit After Tax (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Profit After Tax data on file, last reported at -$219.6 million in Q1 2026.

• Quarterly Profit After Tax fell 575.94% year-over-year to -$219.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$883.1 million (down 644.61% YoY) and the FY2025 annual result came in at -$696.0 million, down 495.29% from the prior year.
• Profit After Tax retreated to -$219.6 million in Q1 2026 per VOR's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Profit After Tax topped out at $1.7 billion in Q4 2025 and bottomed at -$1.6 billion in Q2 2025.
• The 5-year median for Profit After Tax is -$28.4 million (2023), against an average of -$73.1 million.
• Peak annual rise in Profit After Tax reached 5709.72% in 2025, while the deepest fall reached 5552.75% in 2025.
• Tracing VOR's Profit After Tax over 5 years: stood at -$23.9 million in 2022, then dropped by 9.83% to -$26.3 million in 2023, then fell by 16.95% to -$30.7 million in 2024, then surged by 5709.72% to $1.7 billion in 2025, then tumbled by 112.75% to -$219.6 million in 2026.
• Per Business Quant, the three latest VOR Profit After Tax figures stand at -$219.6 million (Q1 2026), $1.7 billion (Q4 2025), and -$812.7 million (Q3 2025).

Peer Comparison